Akebia Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Akebia Therapeutics Reports 2025 Revenue Growth Driven by Vafseo Launch Amidst Auryxia Generic Entry
Akebia Therapeutics saw significant revenue growth in 2025, primarily from the U.S. launch of Vafseo, while navigating generic competition for Auryxia and advancing its rare kidney disease pipeline.
NASDAQ
Akebia Therapeutics details its 2024 financial performance, emphasizing the U.S. launch of Vafseo and advancements in its research and development pipeline.
NASDAQ
Akebia Therapeutics files its 10-K, detailing a warrant agreement, financial performance, and strategic initiatives.